Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types

Trial Profile

Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Germ cell and embryonal neoplasms; Neuroendocrine tumours; Ovarian cancer; Sarcoma; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms AcSe
  • Sponsors UNICANCER
  • Most Recent Events

    • 03 May 2017 Planned initiation date changed from 1 Feb 2017 to 1 Jun 2017.
    • 10 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top